These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 16960964)

  • 1. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
    Kumar N; Griffiths B; Allen J
    J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 4. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil.
    Colglazier CL; Sutej PG; O'Rourke KS
    J Rheumatol; 2005 Dec; 32(12):2440-2. PubMed ID: 16331780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral sildenafil in skin ulcers secondary to systemic sclerosis.
    Della Rossa A; Doveri M; D'Ascanio A; Tavoni A; Consensi A; Neri R; Bazzichi L; Bombardieri S
    Scand J Rheumatol; 2011; 40(4):323-5. PubMed ID: 21639825
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (viagra) in limited systemic sclerosis.
    Yung A; Reay N; Goodfield MD
    Arch Dermatol; 2005 Jul; 141(7):831-3. PubMed ID: 16027296
    [No Abstract]   [Full Text] [Related]  

  • 11. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.
    Lichtenstein JR
    Arthritis Rheum; 2003 Jan; 48(1):282-3; author reply 283. PubMed ID: 12528146
    [No Abstract]   [Full Text] [Related]  

  • 13. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
    Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
    Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil for the treatment of Raynaud's phenomenon.
    Heymann WR
    J Am Acad Dermatol; 2006 Sep; 55(3):501-2. PubMed ID: 16908357
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].
    Rosenkranz S; Caglayan E; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
    Dtsch Med Wochenschr; 2004 Aug; 129(33):1736-40. PubMed ID: 15295684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of Panergon therapy in Raynaud syndrome within the scope of progressive scleroderma].
    Bosmanský K; Tauchmannová H; Lukác J; Zitnan D
    Z Rheumatol; 1985; 44(5):242-5. PubMed ID: 4082792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.